Collaboration and License Agreements - BioMarin Pharmaceutical Inc (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Collaboration and License Agreements
Research and collaboration revenue		$ 1,497	$ 0	$ 2,355	$ 0
BioMarin Pharmaceutical, Inc.
Collaboration and License Agreements
Deferred revenue	$ 1,000					$ 300
Tiered royalties payment, period after first commercial sale	10 years
Fixed consideration amount	$ 3,800
Research and collaboration revenue		900		1,800
Unbilled receivable		$ 300		$ 300
BioMarin Pharmaceutical, Inc. | Maximum
Collaboration and License Agreements
Variable consideration amount, contingent preclinical milestones	5,000
Variable consideration amount, contingent development and regulatory milestones	75,000
Variable consideration amount, commercial sales milestones	$ 105,000
Notice period for termination	270 days
BioMarin Pharmaceutical, Inc. | Minimum
Collaboration and License Agreements
Notice period for termination	30 days